GLP-1 therapy is not exclusively a men's health intervention. The major clinical trials that established GLP-1 efficacy included substantial numbers of women, and the results are compelling across both sexes. But women's metabolic and hormonal physiology differs from men's in clinically meaningful ways, and a well-designed program needs to account for those differences.
This guide addresses everything women need to know about GLP-1 therapy, from efficacy data to hormonal considerations.
GLP-1 Efficacy in Women: What the Trials Show
The landmark GLP-1 trials included women, and the weight loss outcomes are broadly comparable to those seen in men:
- STEP 1 trial (semaglutide): average weight loss of 14.9 percent in the overall population, with women showing similar response to men
- SURMOUNT-1 trial (tirzepatide): average weight loss of 21.4 percent in women at the highest dose, slightly higher than the overall average
Some subgroup analyses suggest women may achieve slightly greater percentage weight loss than men on equivalent GLP-1 protocols, though the clinical difference is modest and individual variation is high.
GLP-1 and PCOS: A Particularly Important Application
Polycystic ovary syndrome (PCOS) affects approximately 20 to 22 percent of Indian women of reproductive age and is closely linked to insulin resistance and androgen excess. GLP-1 therapy addresses the insulin resistance that drives many PCOS features, with documented benefits including:
- Improved menstrual regularity in women with irregular cycles related to PCOS
- Reduced androgen levels (testosterone and free androgen index), leading to improvements in hirsutism and acne
- Improved ovarian function, with some studies showing improved ovulation frequency
- Weight reduction in a population where standard dietary intervention often has limited efficacy
For women with PCOS who have not responded well to metformin or lifestyle changes alone, GLP-1 therapy is a clinically supported option worth discussing with a physician.
GLP-1 and Perimenopause
The perimenopausal and menopausal transition typically involves declining oestrogen, which accelerates visceral fat accumulation, worsens insulin sensitivity, and increases cardiovascular risk. This represents a particularly valuable window for GLP-1 intervention.
Women in perimenopause often notice:
- Increased abdominal fat despite no change in diet or exercise
- Worsening blood sugar control
- Elevation in triglycerides and LDL
- Reduced energy and increased fatigue
GLP-1 therapy directly addresses the visceral adiposity and insulin resistance that drive these changes. For women who are also appropriate candidates for hormone replacement therapy (HRT), the two approaches are complementary and can be used together under physician guidance.
Important Considerations Specific to Women
Contraception and Pregnancy
GLP-1 therapy is contraindicated during pregnancy and breastfeeding. Women of reproductive age who are using GLP-1 therapy should use reliable contraception. If you are planning a pregnancy, discontinuation of GLP-1 therapy at least two months before conception is the standard recommendation.
GLP-1 can reduce the absorption of oral contraceptives due to delayed gastric emptying. If you are on an oral contraceptive pill, discuss this with your physician to ensure continued contraceptive efficacy.
Bone Health
Rapid weight loss of any kind can reduce bone mineral density. This is a consideration for women, particularly post-menopausal women, who already face higher osteoporosis risk. Adequate calcium and vitamin D intake, alongside resistance training, mitigates this risk.
Eating Disorder History
Women with a history of restrictive eating disorders should discuss this with their Longegra physician before starting GLP-1 therapy. The profound appetite suppression produced by these peptides requires careful monitoring in this context.
The Longegra Women's Program
At Longegra, women's intake panels include additional hormonal markers relevant to female metabolic health: oestradiol, FSH, LH, AMH, DHEAS, and fasting androgens where relevant. This allows us to assess whether GLP-1 therapy alone is sufficient or whether hormonal support should be considered alongside it.
We design programs with women's specific physiology in mind, not a male default with adjusted doses.
Frequently Asked Questions (FAQs)
Hormonal fluctuations across the cycle can influence appetite and water retention, which may cause short-term scale fluctuations. GLP-1 efficacy is not significantly affected by the menstrual cycle, but acknowledging these fluctuations helps interpret week-to-week progress accurately.
